INOVIQ
Live / Registered — Registered (as of 17 Dec 2024)
What this means for you
Registered since 17 Dec 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79349962
- Registration number
- 7601786
- Mark type
- Stylized text
- Filed
- 20 May 2022
- Published for opposition
- 15 Oct 2024
- Registered
- 17 Dec 2024
- Attorney of record
- Charles G. Zug
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical, biotechnology and medical preparations and substances for the prevention, diagnosis or treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases; pharmaceutical, biotechnology and medical preparations and substances for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical diagnostic use, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies; immunological antibodies for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicine, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, pharmaceutical and biochemical anti-cancer substances, products for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases, and testing materials, namely, diagnostic test strips, immunoassays, PCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic biomarker reagents; reagents for use in diagnostic tests for medical purposes; reagents for medical diagnosis; proteins for use in recombinant DNA technology for medical diagnosis purposes; proteins, namely protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes
- Class 010 — Medical apparatus: Biotechnology medical apparatus for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases; biotechnology medical apparatus, namely, medical apparatus for the capture of extracellular vesicles; medical diagnostic apparatus and instruments for testing biofluids, plasma, serum, saliva, urine and cell cultures for sale in kit form
- Class 042 — Scientific and technological services: Scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; vaccine screening, in the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research; advisory services relating to diagnostic products for scientific research, namely development of diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; computer-aided diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposes, namely, research services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; research services in the field of diagnostic preparations; preparation of reports relating to medical, scientific and technical research; provision of information relating to medical, scientific and technical research; research and development of products; research and development of products in the field of antibody generation; research and development of products, namely, new therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; scientific laboratory research and analysis services for research and analysis of new products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell line, namely, culturing of cells for others for scientific research purposes
Owner
- INOVIQ Limited, AU
- INOVIQ Limited, AU
- INOVIQ Limited, AU
Prosecution history
- 06 Jun 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 19 May 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 19 May 2025 — FINAL DISPOSITION PROCESSED
- 17 Mar 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 17 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 17 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 15 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Oct 2024 — PUBLISHED FOR OPPOSITION
- 25 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Sept 2024 — EXAMINER'S AMENDMENT ENTERED
- 11 Sept 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 11 Sept 2024 — EXAMINERS AMENDMENT E-MAILED
- 11 Sept 2024 — EXAMINERS AMENDMENT -WRITTEN
- 07 Aug 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED